1. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). (June 2017) Authors: Cramer, P.; von Tresckow, J.; Bahlo, J.; Robrecht, S.; Al‐Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.M.; Fischer, K.; Seiler, T.; von Weikersthal, L.Fischer; Hebart, H.; Kreuzer, K.A.; Ritgen, M.; Kneba, M.; Wendtner, C.M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. (June 2017) Authors: Al‐Sawaf, O.; Bahlo, J.; Fischer, K.; Herling, C.; Bergmann, M.; Fink, A.M.; von Tresckow, J.; Langerbeins, P.; Cramer, P.; Stilgenbauer, S.; Wendtner, C.M.; Eichhorst, B.; Hallek, M.; Goede, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL. (12th June 2019) Authors: Langerbeins, P.; Bahlo, J.; Rhein, C.; Gerwin, H.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; von Tresckow, J.; Fink, A.M.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Müller, L.; Eckart, M.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS‐A). (12th June 2019) Authors: Condoluci, A.; Terzi di Bergamo, L.; Langerbeins, P.; Hoechstetter, M.; Herling, C.; De Paoli, L.; Delgado, J.; Gentile, M.; Doubek, M.; Mauro, F.R.; Chiodin, G.; Mattsson, M.; Bahlo, J.; Cutrona, G.; Kotaskova, J.; Deambrogi, C.; Moia, R.; Gerber, B.; Zucca, E.; Ghielmini, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS. (23rd June 2022) Authors: Cramer, P.; Fürstenau, M.; Giza, A.; Robrecht, S.; Tausch, E.; Schneider, C.; Wendtner, C.-M.; Hoechstetter, M.; Schetelig, J.; Böttcher, S.; Dreger, P.; Fink, A.-M.; Langerbeins, P.; Al-Sawaf, O.; Fischer, K.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗